Skip to content

Corcept misses EPS, beats revenue views; offers above-consensus outlook

May 2, 2017

Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of ($0.06), $0.09 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $27.6 million versus the consensus estimate of $25.53 million.

GUIDANCE:

Corcept Therapeutics sees FY2017 revenue of $125-135 million, versus the consensus of $124 million.

http://bit.ly/2p0CW4P

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: